Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.79 |
| ▸ | EED | O75530 | 4/20 | 0.75 |
| ▸ | RBBP4 | Q09028 | 4/20 | 0.75 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.75 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.63 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474840 | 1.00 | EZH2 (0.79) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL2594401 | 0.91 | EZH2 (0.77) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL2591597 | 0.91 | EZH2 (0.88) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12180688 | 0.89 | EZH2 (0.76) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL2588701 | 0.88 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12180765 | 0.88 | EZH2 (0.76) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL2591198 | 0.88 | EZH2 (0.72) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL16542422 | 0.87 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL2588247 | 0.87 | EZH2 (0.71) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL30122893 | 0.87 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | claimed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | claimed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | claimed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-04-13 | — | — | US | disclosed |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-11-29 | — | — | US | disclosed |
| US-20200338070-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-08-22 | — | — | US | disclosed |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2681216-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2013067300-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566328-A1 | INDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338070-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | EZH2 1/4885EED 3/4885RBBP4 148/4885 |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885RBBP4 2047/4885 |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | EZH2 1/4885EED 3/4885RBBP4 148/4885 |
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | EZH2 1599/4885EED 3742/4885RBBP4 1389/4885 |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | EZH2 1/4885EED 3/4885RBBP4 148/4885 |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885RBBP4 2047/4885 |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885RBBP4 2047/4885 |
| US-20140350013-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | EZH2 1599/4885EED 3742/4885RBBP4 1389/4885 |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | EZH2 1/4885EED 3/4885RBBP4 148/4885 |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | EZH2 1/4885EED 3/4885RBBP4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.